Investors are eyeballing Glaukos IPO

The size and price range have already been increased for Glaukos (GKOS), a medical technology company that plans to price their IPO on Wednesday. Their device is so small it defies imagination but is a proven treatment for glaucoma. 

Three are several reasons the company is experiencing strong demand for their IPO:

• Clinical trials are done and they are in the revenue ramp already. This is a product that is in the early stages of commercial adoption in a large . . .
  

  Want the rest of the article?

  Please login or join us as a member to view our complete content!